CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CHECKVIR aims to develop a novel oncolytic virus-based therapy to treat solid tumors that resist current cancer treatments. By combining tumor cell destruction with immune system activation, this approach seeks to improve outcomes for patients with difficult-to-treat cancers.
Despite novel innovations in immune-oncology over the last decades, up to 80% of solid cancers remain unresponsive to currently available approaches, highlighting an urgent unmet clinical need. CHECKVIR aims to develop and validate a next-generation oncolytic virus-based immunotherapy approach to overcome treatment resistance in solid cancers.
The technology leverages an optimized oncolytic virus platform that is engineered to elicit immune checkpoint inhibitory functions, thereby combining effi…
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
